Ocular Therapeutix (OCUL) closed at $6.21 on November 13, 2026, down 1.1% from the previous close, on volume of 2,331,285 shares (30-day average 2,869,804).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Calendar Call Spread | 15-Jan : 19-Mar-27 8 C | 200 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Needham Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)
TipRanks (Tue, 10-Nov 7:36 AM ET)
RBC Capital Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
TipRanks (Tue, 10-Nov 6:55 AM ET)
Analysts Are Bullish on These Healthcare Stocks: Xenon (XENE), Ocular Therapeutix (OCUL)
TipRanks (Tue, 10-Nov 5:40 AM ET)
TipRanks (Tue, 10-Nov 1:00 AM ET)
Ocular Therapeutix Reports Third Quarter 2026 Financial Results and Business Highlights
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 7:00 AM ET)
Ocular Therapeutix to Report Third Quarter 2026 Financial Results on November 9, 2026
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
Ocular Therapeutix to Participate in November Investor and Scientific Conferences
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Ocular Therapeutix to Participate in October Scientific and Investor Conferences
Globe Newswire (Thu, 1-Oct 7:00 AM ET)
Ocular Therapeutix Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI in Wet AMD
Globe Newswire (Tue, 15-Sep 7:00 AM ET)
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ocular Therapeutix trades on the NASDAQ stock market under the symbol OCUL.
As of November 13, 2026, OCUL stock price declined to $6.21 with 2,331,285 million shares trading.
OCUL has a beta of 1.33, meaning it tends to be more sensitive to market movements. OCUL has a correlation of 0.06 to the broad based SPY ETF.
OCUL has a market cap of $1.36 billion. This is considered a Small Cap stock.
Last quarter Ocular Therapeutix reported $13 million in Revenue and -$.42 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.06.
In the last 3 years, OCUL traded as high as $16.44 and as low as $2.05.
The top ETF exchange traded funds that OCUL belongs to (by Net Assets): VTI, IWM, VXF, PJP, IWO.
OCUL has underperformed the market in the last year with a price return of -44.5% while the SPY ETF gained +13.4%. OCUL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.5% and -10.9%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
OCUL support price is $5.95 and resistance is $6.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCUL shares will trade within this expected range on the day.
